Quantisnow Logo
Dashboard

Chief Accounting Officer Liao Carrie was granted 50,000 shares, increasing direct ownership by 54% to 142,270 units (SEC Form 4)

$MNMD
Medicinal Chemicals and Botanical Products
Health Care
Get the next $MNMD alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $MNMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MNMD

DatePrice TargetRatingAnalyst
1/28/2025$23.00Outperform
Evercore ISI
12/20/2024$20.00Buy
Chardan Capital Markets
10/14/2024$20.00Outperform
Leerink Partners
7/24/2024$36.00Buy
ROTH MKM
5/29/2024$27.00Outperform
Robert W. Baird
4/15/2024$20.00Outperform
Leerink Partners
12/5/2023$9.00Buy
Canaccord Genuity
12/9/2022$25.00Buy
ROTH Capital
More analyst ratings

$MNMD
 Press Releases

Fastest customizable press release news feed in the world

See more

  • MindMed Announces New Employee Inducement Grants

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company (the "Options"), with an effective grant date of March 24, 2025. The Options have an exercise price equal to the closing price of MindMed's common shares on March 21, 2025, the last trading day on which MindMed's common shares traded prior to the date of the grant, and will vest over a four-year period with 25% vesting on the f

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Appoints Matt Wiley as Chief Commercial Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

    --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

$MNMD
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MNMD
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MNMD
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MNMD
 SEC Filings

See more

$MNMD
 Leadership Updates

Live Leadership Updates

See more

  • MindMed Appoints Matt Wiley as Chief Commercial Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

$MNMD
 Financials

Live finance-specific insights

See more

  • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

    --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

    Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

  • MindMed Reports Third Quarter 2024 Financial Results and Business Updates

    --On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.

    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

$MNMD
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more